Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of “Buy” from Analysts

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has earned a consensus rating of “Buy” from the seven research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $8.30.

Several analysts have issued reports on the company. Brookline Capital Management upgraded Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. B. Riley raised shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $1.00 to $1.50 in a research note on Thursday, December 19th. Chardan Capital restated a “buy” rating and set a $11.00 price target on shares of Cognition Therapeutics in a report on Wednesday, February 26th. Finally, HC Wainwright increased their price target on Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Thursday, December 19th.

Cognition Therapeutics Trading Up 7.8 %

NASDAQ:CGTX opened at $0.45 on Friday. Cognition Therapeutics has a twelve month low of $0.34 and a twelve month high of $2.95. The company has a market cap of $18.59 million, a P/E ratio of -0.46 and a beta of 1.04. The company’s 50-day moving average price is $0.62 and its 200-day moving average price is $0.56.

Hedge Funds Weigh In On Cognition Therapeutics

Institutional investors have recently bought and sold shares of the company. BIOS Capital Management LP purchased a new position in shares of Cognition Therapeutics in the fourth quarter valued at approximately $4,208,000. Sigma Planning Corp grew its stake in shares of Cognition Therapeutics by 211.6% in the fourth quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock worth $431,000 after acquiring an additional 417,300 shares in the last quarter. Voss Capital LP acquired a new stake in shares of Cognition Therapeutics in the fourth quarter valued at $351,000. Geode Capital Management LLC boosted its holdings in Cognition Therapeutics by 8.9% in the fourth quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock valued at $247,000 after purchasing an additional 28,705 shares during the period. Finally, Virtu Financial LLC increased its holdings in Cognition Therapeutics by 40.1% during the 4th quarter. Virtu Financial LLC now owns 80,180 shares of the company’s stock worth $56,000 after purchasing an additional 22,949 shares during the period. 43.35% of the stock is owned by institutional investors and hedge funds.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.